Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 35,344 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Back Pain, Low, Back Pain, Back Pain Lower Back Chronic
Interventions: Multimodal approach to QI for Low-Value Care; Behavioral
Lead sponsor: Carilion Clinic; Other
Eligibility: Not listed
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Diabetes Mellitus
Interventions: Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM); Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: PreDiabetes, Diabetes Mellitus, Type 2, Diabetes, Diabetes type2
Interventions: Diabetes Prevention Education and Acceptance and Commitment Therapy, Diabetes Prevention Education Only; Behavioral
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Malignant Pleural Mesothelioma
Interventions: E-Nose testing, Research blood; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 30 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: TEPEZZA, Placebo; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Los Angeles, California • New Haven, Connecticut • Baltimore, Maryland + 3 more

Conditions: Heart Failure
Interventions: Exercise and Cognitive retraining, Exercise Only, Stretching and Flexibility; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 40 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: Sertraline Hydrochloride Tablets 100 mg, Zoloft® Tablets 100 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Sleep Initiation and Maintenance Disorders
Interventions: Cognitive-Behavioral Therapy for Insomnia, zolpidem tartrate (Ambien), Placebo; Behavioral · Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Obstructive Sleep Apnea
Interventions: CPAP4HealthySleep system; Behavioral
Lead sponsor: Sarah Alismail; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Claremont, California

Conditions: Healthy Elderly Volunteers
Interventions: LNK-754; Drug
Lead sponsor: Link Medicine Corporation; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Intracranial Hemorrhage, Traumatic, Intracranial Hemorrhage, Spontaneous
Interventions: Four Factor Prothrombin Complex Concentrate, Fresh Frozen Plasma; Drug · Biological
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Diabetes, Healthy
Interventions: insulin degludec/insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Parents, Self Efficacy, Mental Health Literacy, Psychiatric Emergency
Interventions: iPEACE: Intervention for Parent Education about Care after the ED, Text Messaging Reminders Only; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metastatic Epidural Spinal Cord Compression
Interventions: Stereotactic Radiosurgery (SSRS); Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Postexercise Hypotension
Interventions: Aerobic Exercise, alpha-FMH, Resistance and Aerobic Exercise, Antihistamine; Behavioral · Drug
Lead sponsor: University of Oregon; Other
Eligibility: 18 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Renal Impairment
Interventions: Olorofim; Drug
Lead sponsor: F2G Biotech GmbH; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Osteoarthritis, Knee
Interventions: TissueGene-C, Normal Saline; Biological · Drug
Lead sponsor: Kolon TissueGene, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 5
States / cities: Pinellas Park, Florida • Baltimore, Maryland • Philadelphia, Pennsylvania + 2 more

Conditions: Healthy Men Age 50 Who Are Considering PSA Screening
Interventions: DESI for home viewing, DESI for viewing at Shared Medical Appointment, Option of SMA and DESI or DESI only; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 2,521 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Palo Alto, California • Chapel Hill, North Carolina

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Duvelisib, Ofatumumab; Drug
Lead sponsor: SecuraBio; Industry
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 37
States / cities: La Jolla, California • Denver, Colorado • Altamonte Springs, Florida + 32 more

Conditions: Hepatitis B, Hepatitis C, Liver Disease
Interventions: Video Doctor, PA + PPN; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 431 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Healthy Participants
Interventions: BMS-986172, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Bacterial Infections, Intra-Abdominal Infection, Pneumonia, Bacterial, Skin Diseases, Bacterial, Skin Diseases, Infectious
Interventions: Tygacil; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 8 Years to 11 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 18
States / cities: Long Beach, California • Oakland, California • Orange, California + 15 more

Conditions: Cervical Dystonia
Interventions: Tele-yoga; Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Von Willebrand Diseases
Interventions: VGA039, Placebo; Drug · Other
Lead sponsor: Vega Therapeutics, Inc; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more

Search by objective public record fields.

Quality Improvement re: Choosing Wisely Back Pain Measures

Oral Anti Diabetic Agents in the Hospital

Acceptance and Commitment Therapy Principles for Diabetes Prevention

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Exercise and Cognitive Retraining to Improve Cognition in Heart Failure.

Food Study of Sertraline Hydrochloride Tablets 100 mg and Zoloft® Tablets 100 mg

Combined Behavioral/Pharmacological Therapy for Insomnia

Promoting the Use of CPAP Therapy Among OSA Patients

A Double-Blind, Placebo Controlled, Single, Escalating Dose Study to Evaluate the Preliminary Pharmacokinetics, Safety and Tolerability of LNK-754 in Healthy Elderly Volunteers

FFP Versus PCC in Intracranial Hemorrhage

A Comparison Between Two Formulations of NN5401 in Healthy Subjects

Text-messaging Intervention to Support Parents After Their Child's Psychiatric Emergency

Phase I Study of Feasibility of Single Session Spine Stereotactic Radiosurgery (SSRS) in the Primary Management in Patients With Inoperable, Previously Unirradiated Metastatic Epidural Spinal Cord Compression (MESCC)

Histamine as a Molecular Transducer of Adaptation to Exercise

A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment

Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee

Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1

A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)

Patient-Centered Care and Asian Americans

A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 Absorption

Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age

Tele-yoga and Dystonia

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)